Peritoneal defense mechanisms - The effects of new peritoneal dialysis solutions

Peritoneal Dialysis International

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Kazancioglu, Rumeyza ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Bacteriostatic activity; Host defense; Intracellular microbial killing; Opsonic activity

Indexed keywords

BICARBONATE; CA 125 ANTIGEN; CD14 ANTIGEN; DEFENSIN; DIANEAL; GLUCOSE; HLA DR ANTIGEN; ICODEXTRIN; INTERLEUKIN 1; INTERLEUKIN 6; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PHYSIONEAL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DIALYSIS FLUID;

CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HOST RESISTANCE; HUMAN; LYMPHATIC DRAINAGE; LYMPHOCYTE; MESOTHELIUM CELL; NEUTROPHIL; OPSONIZATION; PERITONEAL DIALYSIS; PERITONEUM CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; CHEMISTRY; CHRONIC KIDNEY FAILURE; DRUG EFFECT; DRUG FORMULATION; METABOLISM; METHODOLOGY; PATHOLOGY; PERITONEUM; PERITONITIS; PHAGOCYTOSIS; PHYSIOLOGY; REVIEW; STANDARD;

DIALYSIS SOLUTIONS; DRUG COMPOUNDING; HUMANS; KIDNEY FAILURE, CHRONIC; MACROPHAGES, PERITONEAL; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PHAGOCYTOSIS;

EID: 67449097795     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Holmes C, Lewis S. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. 2. Humoral defenses. Perit Dial Int 1991; 11: 112-17.
2. Brulez HF, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995; 15(Suppl):S24-34.
3. Dunn DL, Barke RA, Ewald DC, Simmons RL. Macrophages and translymphatic absorption represent the first line of host defense of the peritoneal cavity. Arch Surg 1987; 122: 105-10.
4. Glancey GR, Cameron JS, Ogg CS. Peritoneal drainage: an important element in host defence against staphylococcal peritonitis in patients on CAPD. Nephrol Dial Transplant 1992; 7:627-31.
5. McGregor SJ, Brock JH, Briggs JD, Junor BJ. Longitudinal study of peritoneal defence mechanisms in patients on continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9:115-19.
6. de Fijter CW, Verbrugh HA, Oe LP, Peters ED, van der Meulen J, Donker AJ, et al. Peritoneal defense in continuous ambulatory versus continuous cyclic peritoneal dialysis. Kidney Int 1992; 42:947-50.
7. Brulez HF, Dekker HA, Oe PL, Verbeelen D, ter Wee PM, Verbrugh HA. Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid. Nephron 1996; 74: 26-32.
8. Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients [part 1]. Perit Dial Int 1991; 11:14-21.
9. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24: 327-39.
10. Grupp A, Kimmel M, Fritz P, Voggenreiter B, Stöltzing H, Kuhlmann U, et al. The expression patterns of peritoneal defensins. Perit Dial Int 2007; 27:654-62.
11. Posthuma N, ter Wee P, Donker AJ, Dekker HA, Oe PL, Verbrugh HA. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 1999; 19:334-42.
12. Pecoits-Filho R, Mujais S, Lindholm B. Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int Suppl 2002; (81):S80-7.
13. Vanholder R, Lameire N, Waterloos MA, Van Landschoot N, De Smet R, Vogeleere P, et al. Disturbed host defense in peritoneal cavity during CAPD: characterization of responsible factors in dwell fluid. Kidney Int 1996; 50:643-52.
14. Martikainen TA, Teppo AM, Grönhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25:453-60.
15. Rogachev B, Hausmann MJ, Yulzari R, Weiler M, Holmes C, Faict D, et al. Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFα production by peritoneal macrophages. Perit Dial Int 1997; 17:546-53.
16. Pajek J, Kveder R, Bren A, Gucek A, Ihan A, Osredkar J, et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int 2008; 28: 44-52.
17. ter Wee PM, van Ittersum FJ. The new peritoneal dialysis solutions: friends only, or foes in part? Nat Clin Pract Nephrol 2007; 3:604-12.